Cargando…
ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study
PURPOSE: Low plasma ACTH in critically ill patients may be explained by shock/inflammation-induced hypothalamus-pituitary damage or by feedback inhibition exerted by elevated plasma free cortisol. One can expect augmented/prolonged ACTH-responses to CRH injection with hypothalamic damage, immediatel...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280831/ https://www.ncbi.nlm.nih.gov/pubmed/30374692 http://dx.doi.org/10.1007/s00134-018-5427-y |
_version_ | 1783378744836096000 |
---|---|
author | Peeters, Bram Meersseman, Philippe Vander Perre, Sarah Wouters, Pieter J. Debaveye, Yves Langouche, Lies Van den Berghe, Greet |
author_facet | Peeters, Bram Meersseman, Philippe Vander Perre, Sarah Wouters, Pieter J. Debaveye, Yves Langouche, Lies Van den Berghe, Greet |
author_sort | Peeters, Bram |
collection | PubMed |
description | PURPOSE: Low plasma ACTH in critically ill patients may be explained by shock/inflammation-induced hypothalamus-pituitary damage or by feedback inhibition exerted by elevated plasma free cortisol. One can expect augmented/prolonged ACTH-responses to CRH injection with hypothalamic damage, immediately suppressed responses with pituitary damage, and delayed decreased responses in prolonged critical illness with feedback inhibition. METHODS: This randomized, double-blind, placebo-controlled crossover cohort study, compared ACTH responses to 100 µg IV CRH and placebo in 3 cohorts of 40 matched patients in the acute (ICU-day 3–6), subacute (ICU-day 7–16) or prolonged phase (ICU-day 17–28) of critical illness, with 20 demographically matched healthy subjects. CRH or placebo was injected in random order on two consecutive days. Blood was sampled repeatedly over 135 min and AUC responses to placebo were subtracted from those to CRH. RESULTS: Patients had normal mean ± SEM plasma ACTH concentrations (25.5 ± 1.6 versus 24.8 ± 3.6 pg/ml in healthy subjects, P = 0.54) but elevated free cortisol concentrations (3.11 ± 0.27 versus 0.58 ± 0.05 µg/dl in healthy subjects, P < 0.0001). The order of the CRH/placebo injections did not affect the ACTH responses, hence results were pooled. Patients in the acute phase of illness had normal mean ± SEM ACTH responses (5149 ± 848 pg/mL min versus 4120 ± 688 pg/mL min in healthy subjects; P = 0.77), whereas those in the subacute (2333 ± 387 pg/mL min, P = 0.01) and prolonged phases (2441 ± 685 pg/mL min, P = 0.001) were low, irrespective of sepsis/septic shock or risk of death. CONCLUSIONS: Suppressed ACTH responses to CRH in the more prolonged phases, but not acute phase, of critical illness are compatible with feedback inhibition exerted by elevated free cortisol, rather than by cellular damage to hypothalamus and/or pituitary. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-018-5427-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6280831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-62808312018-12-26 ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study Peeters, Bram Meersseman, Philippe Vander Perre, Sarah Wouters, Pieter J. Debaveye, Yves Langouche, Lies Van den Berghe, Greet Intensive Care Med Original PURPOSE: Low plasma ACTH in critically ill patients may be explained by shock/inflammation-induced hypothalamus-pituitary damage or by feedback inhibition exerted by elevated plasma free cortisol. One can expect augmented/prolonged ACTH-responses to CRH injection with hypothalamic damage, immediately suppressed responses with pituitary damage, and delayed decreased responses in prolonged critical illness with feedback inhibition. METHODS: This randomized, double-blind, placebo-controlled crossover cohort study, compared ACTH responses to 100 µg IV CRH and placebo in 3 cohorts of 40 matched patients in the acute (ICU-day 3–6), subacute (ICU-day 7–16) or prolonged phase (ICU-day 17–28) of critical illness, with 20 demographically matched healthy subjects. CRH or placebo was injected in random order on two consecutive days. Blood was sampled repeatedly over 135 min and AUC responses to placebo were subtracted from those to CRH. RESULTS: Patients had normal mean ± SEM plasma ACTH concentrations (25.5 ± 1.6 versus 24.8 ± 3.6 pg/ml in healthy subjects, P = 0.54) but elevated free cortisol concentrations (3.11 ± 0.27 versus 0.58 ± 0.05 µg/dl in healthy subjects, P < 0.0001). The order of the CRH/placebo injections did not affect the ACTH responses, hence results were pooled. Patients in the acute phase of illness had normal mean ± SEM ACTH responses (5149 ± 848 pg/mL min versus 4120 ± 688 pg/mL min in healthy subjects; P = 0.77), whereas those in the subacute (2333 ± 387 pg/mL min, P = 0.01) and prolonged phases (2441 ± 685 pg/mL min, P = 0.001) were low, irrespective of sepsis/septic shock or risk of death. CONCLUSIONS: Suppressed ACTH responses to CRH in the more prolonged phases, but not acute phase, of critical illness are compatible with feedback inhibition exerted by elevated free cortisol, rather than by cellular damage to hypothalamus and/or pituitary. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-018-5427-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-10-29 2018 /pmc/articles/PMC6280831/ /pubmed/30374692 http://dx.doi.org/10.1007/s00134-018-5427-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Peeters, Bram Meersseman, Philippe Vander Perre, Sarah Wouters, Pieter J. Debaveye, Yves Langouche, Lies Van den Berghe, Greet ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
title | ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
title_full | ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
title_fullStr | ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
title_full_unstemmed | ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
title_short | ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
title_sort | acth and cortisol responses to crh in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280831/ https://www.ncbi.nlm.nih.gov/pubmed/30374692 http://dx.doi.org/10.1007/s00134-018-5427-y |
work_keys_str_mv | AT peetersbram acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy AT meerssemanphilippe acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy AT vanderperresarah acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy AT wouterspieterj acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy AT debaveyeyves acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy AT langouchelies acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy AT vandenberghegreet acthandcortisolresponsestocrhinacutesubacuteandprolongedcriticalillnessarandomizeddoubleblindplacebocontrolledcrossovercohortstudy |